Ranbaxy recalls nearly 30,000 packs of allergy-relief drug in U.S

MUMBAI Fri May 2, 2014 4:42pm IST

A general view of the office of Ranbaxy Laboratories is pictured at Gurgaon, on the outskirts of New Delhi, June 13, 2013. REUTERS/Adnan Abidi/Files

A general view of the office of Ranbaxy Laboratories is pictured at Gurgaon, on the outskirts of New Delhi, June 13, 2013.

Credit: Reuters/Adnan Abidi/Files

Related Topics

Stocks

   

MUMBAI (Reuters) - Drugmaker Ranbaxy Laboratories Ltd (RANB.NS) started recalling 29,790 packs of an allergy-relief medicine in the United States in February, after finding defects in the packaging, the U.S. Food and Drug Administration said.

The loratadine and pseudoephedrine sulphate extended release tablets being recalled carry an expiry date of September 2015, and were manufactured by Ranbaxy's Ohm Labs plant in New Jersey, which is the company's only facility making generics for the United States.

All other Ranbaxy plants, based in India, have been banned from exporting generics to the United States after the FDA found manufacturing quality glitches that the agency believed could compromise the quality of medicines.

Rival Indian drugmaker Sun Pharmaceutical Industries Ltd (SUN.NS) agreed to buy Ranbaxy last month in a $3.2 billion deal, betting it can fix Ranbaxy's problems.

The FDA classified the recall by Ohm Labs as Class II, which means use of or exposure to the recalled products may cause temporary or medically reversible adverse health consequences.

Ranbaxy did not immediately respond to requests for comment.

(Reporting by Zeba Siddiqui in MUMBAI; Editing by Subhranshu Sahu)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Shares Hit Record

Sensex, Nifty rise to second consecutive record high

Sensex surges 500 points on BOJ easing, L&T gains

The BSE Sensex and Nifty surged to record highs for a second consecutive session on Friday after Bank of Japan's surprise expansion of its massive stimulus programme raised hopes for additional foreign inflows, boosting blue-chips such as Larsen & Toubro.  Full Article 

REUTERS SHOWCASE

Ban on E-Cigs?

Ban on E-Cigs?

Govt considers ban on e-cigarettes, sale of single smokes.  Full Article 

Commodities

Commodities

Silver futures in India hit four-year low on global cues.  Full Article 

BOJ Policy

BOJ Policy

BOJ shocks markets with surprise easing as inflation slows.  Full Article 

Cost Cutting

Cost Cutting

PM Narendra Modi boots officials out of the first class cabin  Full Article 

Leisure Riding

Leisure Riding

Harley-Davidson woos affluent young Indians with bike culture  Full Article 

Shadow Banking

Shadow Banking

China's shadow banking sector growing rapidly, third largest in world - FSB.  Full Article 

Moody's on India

Moody's on India

Moody's welcomes India's policy steps, but wants to see more.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage